Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5057052> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q5057052 subject Q8431759.
- Q5057052 subject Q8546974.
- Q5057052 subject Q8616356.
- Q5057052 subject Q8636858.
- Q5057052 subject Q8808791.
- Q5057052 subject Q8955377.
- Q5057052 subject Q8965786.
- Q5057052 abstract "Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.On February 27, 2008, AstraZeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab. As of November 2012, it was being assessed in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20 mg daily dose.".
- Q5057052 atcPrefix "L01".
- Q5057052 atcSuffix "XE32".
- Q5057052 casNumber "288383-20-0".
- Q5057052 fdaUniiCode "NQU9IPY4K9".
- Q5057052 iupacName "4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline".
- Q5057052 pubchem "9933475".
- Q5057052 thumbnail AZD2171.svg?width=300.
- Q5057052 wikiPageExternalLink 15602_15632_9_3_1.aspx.
- Q5057052 wikiPageWikiLink Q188874.
- Q5057052 wikiPageWikiLink Q2843019.
- Q5057052 wikiPageWikiLink Q29725.
- Q5057052 wikiPageWikiLink Q30612.
- Q5057052 wikiPageWikiLink Q309510.
- Q5057052 wikiPageWikiLink Q3242950.
- Q5057052 wikiPageWikiLink Q413299.
- Q5057052 wikiPageWikiLink Q47273.
- Q5057052 wikiPageWikiLink Q47912.
- Q5057052 wikiPageWikiLink Q7083106.
- Q5057052 wikiPageWikiLink Q7251487.
- Q5057052 wikiPageWikiLink Q731938.
- Q5057052 wikiPageWikiLink Q8431759.
- Q5057052 wikiPageWikiLink Q8546974.
- Q5057052 wikiPageWikiLink Q8616356.
- Q5057052 wikiPageWikiLink Q8636858.
- Q5057052 wikiPageWikiLink Q8808791.
- Q5057052 wikiPageWikiLink Q8955377.
- Q5057052 wikiPageWikiLink Q8965786.
- Q5057052 atcPrefix "L01".
- Q5057052 atcSuffix "XE32".
- Q5057052 casNumber "288383".
- Q5057052 iupacName "4".
- Q5057052 pubchem "9933475".
- Q5057052 unii "NQU9IPY4K9".
- Q5057052 type ChemicalSubstance.
- Q5057052 type Drug.
- Q5057052 type ChemicalObject.
- Q5057052 type Thing.
- Q5057052 type Q8386.
- Q5057052 comment "Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children.".
- Q5057052 label "Cediranib".
- Q5057052 depiction AZD2171.svg.